@article {Carrollpractneurol-2020-002837, author = {Antonia S Carroll and Michael P T Lunn}, title = {Paraproteinaemic neuropathy: MGUS and beyond}, elocation-id = {practneurol-2020-002837}, year = {2021}, doi = {10.1136/practneurol-2020-002837}, publisher = {BMJ Publishing Group Ltd}, abstract = {Paraproteinaemic neuropathies comprise a heterogeneous group of neuro-haematological conditions with some distinct neurological, haematological and systemic phenotypes. The spectrum of disease varies from mild to severe, indolent to rapidly progressive and from small fibre sensory involvement to dramatic sensorimotor deficits. The haematological association may be overlooked, resulting in delayed treatment, disability, impaired quality of life and increased mortality. However, the presence of an irrelevant benign paraprotein can sometimes lead to inappropriate treatment. In this review, we outline our practical approach to paraproteinaemic disorders, discuss the utility and limitations of diagnostic tests and the distinctive clinical phenotypes and touch on the complex multidisciplinary management approaches.}, issn = {1474-7758}, URL = {https://pn.bmj.com/content/early/2021/07/18/practneurol-2020-002837}, eprint = {https://pn.bmj.com/content/early/2021/07/18/practneurol-2020-002837.full.pdf}, journal = {Practical Neurology} }